Metronidazole, sold as Flagyl, was dropped as a first-line treatment for C. diff infections because it simply doesn’t work as well as the alternatives. The 2017 IDSA/SHEA guidelines formally recommended vancomycin or fidaxomicin over metronidazole, and the 2021 update went further, stating that standard-of-care antibiotics for C. diff “now include fidaxomicin and vancomycin, but not metronidazole.” It’s not banned entirely, but it’s been pushed to a last-resort role for mild cases when nothing else is available.
Lower Cure Rates, Especially in Severe Cases
The core problem is effectiveness. In a key clinical trial comparing the two drugs, metronidazole cured 84% of C. diff patients overall, while vancomycin cured 97%. That gap was most dramatic in severe infections: metronidazole cured only 76% of severe cases compared to 97% for vancomycin. For mild disease, the difference was smaller (90% vs. 98%) and not statistically significant, which is why guidelines still allow metronidazole as a fallback for mild infections when cost or access is a barrier.
Multiple randomized controlled trials have confirmed this pattern. The evidence became strong enough that by 2017, major infectious disease organizations made the switch official.
How Metronidazole Works Against It in the Gut
One reason metronidazole underperforms comes down to how the drug behaves inside the colon. C. diff lives in the large intestine, so a drug needs to reach adequate concentrations there to kill it. Metronidazole is absorbed into the bloodstream from the upper digestive tract and only reaches the colon indirectly, through secretion back into the gut when the intestinal lining is inflamed.
Here’s the catch: as treatment starts working and inflammation improves, less metronidazole makes it into the colon. Studies have shown that metronidazole levels in stool drop as diarrhea resolves, and the drug becomes undetectable in stool once a patient recovers. This creates a window where drug levels may be too low to finish off the infection, potentially allowing surviving bacteria to rebound. Vancomycin, by contrast, is taken orally but stays in the gut without being absorbed into the bloodstream, maintaining high concentrations in the colon throughout the full course of treatment.
Neurological Side Effects
Metronidazole also carries a risk of nerve damage that vancomycin and fidaxomicin do not. Nearly 100 case reports of suspected metronidazole-related neurotoxicity have been published, involving both the brain and peripheral nerves. The peripheral nerve damage typically shows up as a slowly worsening numbness and pain in the hands and feet, often with severe pain, and it frequently leads to permanent disability. Brain-related effects include a distinctive pattern of cerebellar dysfunction (problems with coordination, slurred speech, and involuntary eye movements), though these are usually reversible, with about two-thirds of affected patients recovering completely.
The overall incidence is low. Among metronidazole recipients in one large study, neurological events occurred in roughly 0.25% of patients within 100 days. But when a safer, more effective drug exists, even a small risk of permanent nerve damage tips the balance. Compared to similar antibiotics, metronidazole carried a 43% higher adjusted odds of neurological side effects.
Where Fidaxomicin Fits In
The 2021 guidelines didn’t just confirm vancomycin over metronidazole. They went a step further, suggesting fidaxomicin as the preferred option over vancomycin for both initial and recurrent C. diff episodes. Like vancomycin, fidaxomicin stays in the gut rather than being absorbed systemically. It also has a narrower spectrum of activity, meaning it kills C. diff while doing less damage to the other beneficial bacteria in the colon. This matters because disrupting the gut microbiome is what makes C. diff infections so prone to coming back.
The guideline panel acknowledged that fidaxomicin’s higher cost could be a barrier and noted that vancomycin “remains an acceptable alternative.” The treatment hierarchy now runs: fidaxomicin first, vancomycin second, metronidazole as a distant third only for nonsevere cases when the other two are unavailable.
When Metronidazole Is Still Used
Metronidazole hasn’t disappeared entirely from C. diff treatment. There are specific situations where it still has a role:
- Limited access to alternatives. In settings where vancomycin or fidaxomicin is unavailable or unaffordable, metronidazole remains an option for a first episode of nonsevere C. diff. Nonsevere is defined as a white blood cell count of 15,000 or lower and a creatinine level below 1.5 mg/dL.
- Fulminant (life-threatening) cases, as an add-on. In the most severe infections where the bowel has stopped moving normally, intravenous metronidazole is given alongside oral or rectal vancomycin. This is the one scenario where its absorption into the bloodstream is actually an advantage, since it can reach the colon through the blood supply when oral drugs can’t pass through a paralyzed gut.
- Children. Guidelines are more permissive for pediatric patients, allowing either metronidazole or vancomycin for initial or first-recurrence nonsevere infections in children.
Outside these narrow circumstances, metronidazole is no longer considered appropriate. The shift reflects years of accumulating evidence that it’s both less effective and less safe than the alternatives now available.